Integral Health Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Integral Health Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100,000	Closed	-$2.06M	–	92
2024 Q3	$2.06M	Buy	+100,000	New	+$2.31M	0.23%	60
2023 Q3	–	Sell	-206,000	Closed	-$8.4M	–	82
2023 Q2	$8.4M	Buy	+206,000	New	+$8.35M	1.04%	40
2023 Q1	–	Sell	-150,000	Closed	-$5.23M	–	84
2022 Q4	$5.23M	Buy	150,000 +25,000	+20%	+$1.19M	1.1%	35
2022 Q3	$7M	Buy	125,000 +41,505	+50%	+$2.57M	1.36%	30
2022 Q2	$4.32M	Buy	83,495 +33,495	+67%	+$1.7M	0.89%	39
2022 Q1	$3.63M	Hold	50,000	–	–	0.95%	37
2021 Q4	$5.91M	Hold	50,000	–	–	1.64%	24
2021 Q3	$6.71M	Buy	50,000 +20,000	+67%	+$3.03M	1.93%	16
2021 Q2	$4.86M	Sell	30,000 -140,000	-82%	-$10.9M	1.34%	30
2021 Q1	$13.6M	Buy	170,000 +110,000	+183%	+$7.38M	3.9%	5
2020 Q4	$3.26M	Buy	+60,000	New	+$2.18M	0.97%	36

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Integral Health Asset Management's NTLA Position: Q4 2024 in Review

Integral Health Asset Management sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 100,000 shares — an estimated $2.06M sold.

Integral Health Asset Management first reported a position in NTLA in Q4 2020 and held it in 11 quarters. The position peaked at $13.6M in Q1 2021. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

Integral Health Asset Management reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
Integral Health Asset Management sold 100,000 Intellia Therapeutics shares in Q4 2024, an estimated $2.06M.
Integral Health Asset Management first reported a position in Intellia Therapeutics in Q4 2020 and held it in 11 quarters.
Integral Health Asset Management's Intellia Therapeutics position peaked at $13.6M in Q1 2021.
293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Integral Health Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.